Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	207.56B
Revenue (ttm)	12.11B
Net Income (ttm)	1.77B
Shares Out	382.57M
EPS (ttm)	6.88
PE Ratio	78.87
Forward PE	40.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	345,767
Average Volume	925,725
Open	546.50
Previous Close	549.10
Day's Range	533.55 - 548.90
52-Week Range	533.55 - 1,342.00
Beta	0.52
RSI	18.36
Earnings Date	Nov 12, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.